* Q4 loss $0.25/shr vs est loss $0.31/shr
* Q4 revenue up 38 pct at $48 mln
* Says US sales of testosterone drug strong
* Sees '10 revenue of $185-$195 mln from Testim
Feb 17 Auxilium Pharmaceuticals Inc AUXL.O
posted a narrower-than-expected quarterly loss, helped by
strong sales of Testim, its gel to treat low testosterone, in
the United States.
For the latest fourth quarter, the company reported a net
loss of $11.9 million, or 25 cents a share, compared with a
loss of $12.1 million, or 29 cents a share, a year earlier.
Analysts on average had expected a loss of 31 cents a
share, excluding special items, on revenue of $44.3 million,
according to Thomson Reuters I/B/E/S.
Revenue rose 38 percent to $48.0 million.
U.S. sales of Testim rose to $42.3 million from $34.0
million in the year-ago quarter.
For 2010, the company expects Testim revenue of $185
million to $195 million.
The company also said it has priced its drug Xiaflex to
distributors at $3,250 per vial.
Earlier this month, U.S. regulators had approved Xiaflex
for treating a progressive hand disease known as Dupuytren's
contracture, and the company plans a launch for late March.
Shares of the company were up about 1 percent in trading
before the bell. They closed at $31.70 Tuesday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by